BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CSL Behring Launches MySource™ at the National Hemophilia Foundation's 65th Annual Meeting


10/3/2013 8:13:01 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

ANAHEIM, Calif., Oct. 3, 2013 /PRNewswire/ -- People who are living with a rare and serious bleeding disorder will now have one-stop access to educational resources, financial support, and community connection programs through CSL Behring's MySource program. Launched during the National Hemophilia Foundation's (NHF) 65th Annual Meeting, MySource allows patients, caregivers and healthcare professionals to quickly and easily access CSL Behring's patient-support resources at one online location www.MySourceCSL.com or with a one-on-one care coordinator (at 1-800-676-4266).

(Logo: http://photos.prnewswire.com/prnh/20130627/NY39350LOGO )

"CSL Behring has a broad portfolio of coagulation products, a long history of advancing coagulation therapy, and a thorough understanding of the challenges facing the bleeding disorders community," said Lynne Powell, Senior Vice President, North America Commercial Operations, CSL Behring. "We are committed to providing treatments and supportive services, like MySource, that make a meaningful difference in the lives of people with bleeding disorders and those who care for them. We are proud to launch the program during NHF's annual meeting."

CSL Behring created MySource to provide members of the bleeding disorders community with a single source of information that will enhance their treatment experience. MySource is also designed to meet the specific needs and preferences of each patient by providing customized information each time they visit. MySource offers:

  • Education opportunities that provide members of the bleeding disorders community with information about hemophilia and von Willebrand disease (VWD)
  • Financial support programs to help ensure individuals are able to access their treatment
  • Community connections that allow members of the bleeding disorders community to share experiences with one another, both online and in person

"For those living with a bleeding disorder, it can be difficult to find a central location for information about their condition. It can also be difficult to connect with a community for help in navigating the challenges associated with a bleeding disorder," said Timothy Grams, who lives with severe hemophilia A. "The new MySource resource is a welcome addition to address this need. The site provides a wealth of information for patients and caregivers alike who are looking to learn more about the condition that affects them or to connect with others who share similar experiences and challenges."

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.

Media Contact:
Greg Healy
Senior Manager, Public Relations & Communications
CSL Behring
1-610-878-4841
greg.healy@cslbehring.com

Madeleine Desmond
Weber Shandwick
1-212-454-8293
MDesmond@webershandwick.com

SOURCE CSL Behring



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES